Trailing-twelve-month (TTM) revenue is $323.93 Million with a year-over-year growth of +6.83%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $84,069,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-07 |
| Q4 FY2025Period ended 2025-12-31 | $83,336,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-27 |
| Q1 FY2026Period ended 2026-03-31 | $71,138,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $85,389,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $323,932,000 |
Current P/S: $600,505,613 market capitalization ÷ $323,932,000 TTM revenue = 1.85x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:05:19.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $85.39M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:06:39.729Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|
| Laboratory Services | $289M | $283M | $322M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| CANADA | $2M | N/A | N/A | N/A | N/A | N/A |
| CHINA | N/A | N/A |
$323.93M
$323.93 Million
+6.83%
vs. $303.22M a year ago (TTM)
(18.66%)
5 Year compound annual growth rate
1 Year
+6.83%
3 Year
+1.76%
5 Year
(18.66%)
10 Year
+37.71%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $322.67M | +$39.20M | +13.83% |
| 2024 | $283.47M | ($5.74M) | (1.99%) |
| 2023 | $289.21M | ($329.75M) | (53.27%) |
| 2022 | $618.97M | ($373.62M) | (37.64%) |
| 2021 | $992.58M | +$570.87M | +135.37% |
| 2020 |
TTM Growth
+6.83%
3-Year CAGR
+1.76%
5-Year CAGR
(18.66%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 25 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:06:39.729Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| $13M |
| $13M |
| Non Us | N/A | $14M | N/A | N/A | N/A | N/A |
|---|
| Non-US | N/A | N/A | $16M | $20M | $24M | $26M |
|---|
| Other Countries | $5M | N/A | N/A | N/A | $12M | $13M |
|---|
| UNITED STATES | $415M | $979M | $603M | $269M | $259M | N/A |
|---|
| US | N/A | N/A | N/A | N/A | N/A | $297M |
|---|
| $421.71M |
| +$389.18M |
| +1196.46% |
| 2019 | $32.53M | +$11.17M | +52.31% |
| 2018 | $21.36M | +$2.63M | +14.03% |
| 2017 | $18.73M | +$454,000 | +2.48% |
| 2016 | $18.28M | +$8.70M | +90.85% |
